Altered biomarkers in trophoblast cells obtained noninvasively prior to clinical manifestation of perinatal disease

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Bolnick, Jay M ^a   Kohan Ghadr, Hamid Reza ^a   Fritz, Rani ^a   Bolnick, Alan D ^a   Kilburn, Brian A ^a   Diamond, Michael P ^b   Armant, D Randall ^a,c   Drewlo, Sascha ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84988810069     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep32382     Document Type: Article

References (52)

1. Grill, S., et al. Potential markers of preeclampsia-a review. Reproductive biology and endocrinology: RB&E 7, 70, doi: 10.1186/1477-7827-7-70 (2009).
2. Maynard, S., Epstein, F. H. & Karumanchi, S. A. Preeclampsia and angiogenic imbalance. Annu. Rev. Med. 59, 61-78, doi: 10.1146/annurev.med.59.110106.214058 (2008).
3. Myatt, L., et al. The utility of uterine artery Doppler velocimetry in prediction of preeclampsia in a low-risk population. Obstet. Gynecol. 120, 815-822, doi: 10.1097/AOG.0b013e31826af7fb (2012).
4. Khong, T. Y., De Wolf, F., Robertson, W. B. & Brosens, I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br. J. Obstet. Gynaecol. 93, 1049-1059 (1986).
5. Brosens, I. A., Robertson, W. B. & Dixon, H. G. The role of the spiral arteries in the pathogenesis of preeclampsia. Obstet. Gynecol. Annu. 1, 177-191 (1972).
6. DiFederico, E., Genbacev, O. & Fisher, S. J. Preeclampsia is associated with widespread apoptosis of placental cytotrophoblasts within the uterine wall. Am. J. Pathol. 155, 293-301 (1999).
7. Ishihara, N., et al. Increased apoptosis in the syncytiotrophoblast in human term placentas complicated by either preeclampsia or intrauterine growth retardation. Am. J. Obstet. Gynecol. 186, 158-166 (2002).
8. Allaire, A. D., Ballenger, K. A., Wells, S. R., McMahon, M. J. & Lessey, B. A. Placental apoptosis in preeclampsia. Obstet. Gynecol. 96, 271-276 (2000).
9. Burton, G. J. & Jauniaux, E. Placental oxidative stress: from miscarriage to preeclampsia. J. Soc. Gynecol. Investig. 11, 342-352, doi: 10.1016/j.jsgi.2004.03.003S1071-5576(04)00138-8 (2004).
10. Roberts, J. M. Endothelial dysfunction in preeclampsia. Semin. Reprod. Endocrinol. 16, 5-15 (1998).
11. Redman, C. W. & Sargent, I. L. Placental debris, oxidative stress and pre-eclampsia. Placenta 21, 597-602 (2000).
12. Wapner, R. J. Invasive prenatal diagnostic techniques. Semin. Perinatol. 29, 401-404, doi: 10.1053/j.semperi.2006.01.003 (2005).
13. Imudia, A. N., Kumar, S., Diamond, M. P., Decherney, A. H. & Armant, D. R. Transcervical retrieval of fetal cells in the practice of modern medicine: a review of the current literature and future direction. Fertil. Steril. 93, 1725-1730, doi: S0015-0282(09)04051-5 10.1016/j.fertnstert.2009.11.022 (2010).
14. Shettles, L. B. Use of the Y chromosome in prenatal sex determination. Nature 230, 52-53 (1971).
15. Chou, M. M., Lin, S. K. & Ho, E. S. Severe limb reduction defects after uterine lavage at 7-8 weeks gestation. Prenatal diagnosis 17, 77-80 (1997).
16. Kingdom, J., Sherlock, J., Rodeck, C. & Adinolfi, M. Detection of trophoblast cells in transcervical samples collected by lavage or cytobrush. Obstetrics and gynecology 86, 283-288 (1995).
17. Fejgin, M. D., Diukman, R., Cotton, Y., Weinstein, G. & Amiel, A. Fetal cells in the uterine cervix: a source for early non-invasive prenatal diagnosis. Prenatal diagnosis 21, 619-621 (2001).
18. Paraiso, M. F., Brady, K., Helmchen, R. & Roat, T. W. Evaluation of the endocervical Cytobrush and Cervex-Brush in pregnant women. Obstet. Gynecol. 84, 539-543 (1994).
19. Holt, J., Stiltner, L., Jamieson, B. & Fashner, J. Clinical inquiries. Should a nylon brush be used for Pap smears from pregnant women? J. Fam. Pract. 54, 463-464, doi: jfp-0505-5405n (2005).
20. Orr, J. W. Jr., Barrett, J. M., Orr, P. F., Holloway, R. W. & Holimon, J. L. The efficacy and safety of the cytobrush during pregnancy. Gynecol. Oncol. 44, 260-262 (1992).
21. Rivlin, M. E., et al. Comparison of cytobrush and cotton swab for Papanicolaou smears in pregnancy. J. Reprod. Med. 38, 147-150 (1993).
22. Loke, Y. W., et al. Evaluation of trophoblast HLA-G antigen with a specific monoclonal antibody. Tissue Antigens 50, 135-146 (1997).
23. Imudia, A. N., et al. Retrieval of trophoblast cells from the cervical canal for prediction of abnormal pregnancy: a pilot study. Hum. Reprod. 24, 2086-2092, doi: dep206 10.1093/humrep/dep206 (2009).
24. Bolnick, J. M., et al. Trophoblast retrieval and isolation from the cervix (TRIC) for noninvasive prenatal screening at 5 to 20 weeks of gestation. Fertil. Steril. 102, 135-142 e136, doi: 10.1016/j.fertnstert.2014.04.008 (2014).
25. Fritz, R., et al. Noninvasive detection of trophoblast protein signatures linked to early pregnancy loss using trophoblast retrieval and isolation from the cervix (TRIC). Fertil. Steril. 104, 339-346 e334, doi: 10.1016/j.fertnstert.2015.05.010 (2015).
26. Huppertz, B., Meiri, H., Gizurarson, S., Osol, G. & Sammar, M. Placental protein 13 (PP13): a new biological target shifting individualized risk assessment to personalized drug design combating pre-eclampsia. Human reproduction update 19, 391-405, doi: 10.1093/humupd/dmt003 (2013).
27. Than, N. G., et al. Evolutionary origins of the placental expression of chromosome 19 cluster galectins and their complex dysregulation in preeclampsia. Placenta 35, 855-865, doi: 10.1016/j.placenta.2014.07.015 (2014).
28. Smith, G. C., et al. Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J. Clin. Endocrinol. Metab. 87, 1762-1767 (2002).
29. Nucci, M., Poon, L. C., Demirdjian, G., Darbouret, B. & Nicolaides, K. H. Maternal Serum Placental Growth Factor (PlGF) Isoforms and 2 at 11-13 Weeks Gestation in Normal and Pathological Pregnancies. Fetal diagnosis and therapy, doi: 10.1159/000357842 (2014).
30. Ghosh, S. K., Raheja, S., Tuli, A., Raghunandan, C. & Agarwal, S. Can maternal serum placental growth factor estimation in early second trimester predict the occurrence of early onset preeclampsia and/or early onset intrauterine growth restriction? A prospective cohort study. The journal of obstetrics and gynaecology research 39, 881-890, doi: 10.1111/jog.12006 (2013).
31. Farina, A., et al. Gene expression in chorionic villous samples at 11 weeks gestation from women destined to develop preeclampsia. Prenatal diagnosis 28, 956-961, doi: 10.1002/pd.2109 (2008).
32. Levine, R. J., et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350, 672-683, doi: 10.1056/NEJMoa031884 (2004).
33. Chung, J. Y., Song, Y., Wang, Y., Magness, R. R. & Zheng, J. Differential expression of vascular endothelial growth factor (VEGF), endocrine gland derived-VEGF, and VEGF receptors in human placentas from normal and preeclamptic pregnancies. The Journal of clinical endocrinology and metabolism 89, 2484-2490, doi: 10.1210/jc.2003-031580 (2004).
34. Williams, M. A., et al. Elevated maternal serum alpha-fetoprotein levels and midtrimester placental abnormalities in relation to subsequent adverse pregnancy outcomes. American journal of obstetrics and gynecology 167, 1032-1037 (1992).
35. Waller, D. K., Lustig, L. S., Cunningham, G. C., Feuchtbaum, L. B. & Hook, E. B. The association between maternal serum alphafetoprotein and preterm birth, small for gestational age infants, preeclampsia, and placental complications. Obstetrics and gynecology 88, 816-822 (1996).
36. Lai, J., Syngelaki, A., Poon, L. C., Nucci, M. & Nicolaides, K. H. Maternal serum soluble endoglin at 30-33 weeks in the prediction of preeclampsia. Fetal Diagn Ther 33, 149-155, doi: 10.1159/000343220 (2013).
37. Milne, F., et al. The pre-eclampsia community guideline (PRECOG): how to screen for and detect onset of pre-eclampsia in the community. BMJ 330, 576-580, doi: 10.1136/bmj.330.7491.576 (2005).
38. Stanek, J. & Biesiada, J. Clustering of maternal-fetal clinical conditions and outcomes and placental lesions. American journal of obstetrics and gynecology 206, 493.e491-e498, doi: 10.1016/j.ajog.2012.03.025 (2012).
39. Than, N. G., et al. A primate subfamily of galectins expressed at the maternal-fetal interface that promote immune cell death. Proc. Natl. Acad. Sci. USA. 106, 9731-9736, doi: 10.1073/pnas.0903568106 (2009).
40. Romero, R., et al. First-trimester maternal serum PP13 in the risk assessment for preeclampsia. American journal of obstetrics and gynecology 199, 122 e121-122 e111, doi: 10.1016/j.ajog.2008.01.013 (2008).
41. Morris, R. K., et al. Serum screening with Downs syndrome markers to predict pre-eclampsia and small for gestational age: systematic review and meta-analysis. BMC pregnancy and childbirth 8, 33, doi: 10.1186/1471-2393-8-33 (2008).
42. Conde-Agudelo, A., Papageorghiou, A. T., Kennedy, S. H. & Villar, J. Novel biomarkers for predicting intrauterine growth restriction: a systematic review and meta-analysis. BJOG 120, 681-694, doi: 10.1111/1471-0528.12172 (2013).
43. Metcalfe, A., Langlois, S., Macfarlane, J., Vallance, H. & Joseph, K. S. Prediction of obstetrical risk using maternal serum markers and clinical risk factors. Prenat. Diagn. 34, 172-179, doi: 10.1002/pd.4281 (2014).
44. Hagmann, H., Thadhani, R., Benzing, T., Karumanchi, S. A. & Stepan, H. The promise of angiogenic markers for the early diagnosis and prediction of preeclampsia. Clin. Chem. 58, 837-845, doi: 10.1373/clinchem.2011.169094 (2012).
45. Gao, J., et al. Value of second trimester maternal serum sFlt-1, PlGF and their ratio in the prediction of preeclampsia. Zhonghua Fu Chan Ke Za Zhi 49, 22-25 (2014).
46. Prefumo, F. Re: Uterine artery Doppler and sFlt-1/PlGF ratio: prognostic value in early-onset pre-eclampsia. Gomez-Arriaga, P. I., Herraiz, I., Lopez-Jimenez, E. A., Escribano, D., Denk, B. and Galindo, A. Ultrasound Obstet Gynecol 2014; 43: 525-532. Ultrasound Obstet Gynecol 43, 488-489, doi: 10.1002/uog.13362 (2014).
47. Allen, R. E., Rogozinska, E., Cleverly, K., Aquilina, J. & Thangaratinam, S. Abnormal blood biomarkers in early pregnancy are associated with preeclampsia: a meta-analysis. Eur J Obstet Gynecol Reprod Biol 182, 194-201, doi: 10.1016/j.ejogrb.2014.09.027 (2014).
48. Hossain, N. & Paidas, M. J. Adverse pregnancy outcome, the uteroplacental interface, and preventive strategies. Semin. Perinatol. 31, 208-212, doi: 10.1053/j.semperi.2007.05.002 (2007).
49. Papageorghiou, A. T., Yu, C. K. & Nicolaides, K. H. The role of uterine artery Doppler in predicting adverse pregnancy outcome. Best Pract Res Clin Obstet Gynaecol 18, 383-396, doi: 10.1016/j.bpobgyn.2004.02.003 (2004).
50. Redman, C. W. & Sargent, I. L. Latest advances in understanding preeclampsia. Science (Wash.DC) 308, 1592-1594 (2005).
51. Zhou, Y., Damsky, C. H. & Fisher, S. J. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? J. Clin. Invest. 99, 2152-2164 (1997).
52. Guttmacher, A. E., Maddox, Y. T. & Spong, C. Y. The Human Placenta Project: placental structure, development, and function in real time. Placenta 35, 303-304, doi: 10.1016/j.placenta.2014.02.012 (2014).